期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 172, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejps.2022.106141
关键词
Serum albumins; Protein binding; Time resolved emission
资金
- KSCSTE
This study investigates the interaction between a pyridine derivative called HDN and serum albumins. The results reveal a moderate binding affinity of HDN with albumins and minimal impact on the protein's secondary structure. This suggests the potential application of HDN as an effective drug.
The successful evolution of an effective drug depends on its pharmacokinetics, efficiency and safety and these in turn depend on the drug-target/drug-carrier protein binding. This work, deals with the interaction of a pyridine derivative, 2-hydroxy-5-(4-methoxyphenyl)-6-phenylpyridine 3-carbonitrile (HDN) with serum albumins at physiological conditions utilizing the steady state and time-resolved fluorescence techniques by probing the emission behavior of Trp in BSA and HSA. In-silico studies revealed a combined static and dynamic quenching mechanism for the interactions. The binding studies suggests a spontaneous binding between HDN and the albumins with a moderate binding affinity (Kb similar to 10(-5) M-1) with a single class of binding site. The FRET mediated emission from HDN indicates preferential binding of HDN in subdomain IIA of the albumins with Trp residue in close proximity. Circular dichroism results indicate HDN induced conformational changes for BSA and HSA, but the alpha-helical secondary structure was well preserved even up to a concentration of 10 mu M HDN. Moderate binding affinity of HDN with BSA and HSA and the unaltered secondary structure of proteins on binding propose the potential application of HDN as an efficient drug. The application of docking method on the affinity of HDN towards the proposed target/receptor is discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据